NASDAQ:TOI Oncology Institute (TOI) Stock Price, News & Analysis $5.85 +0.20 (+3.54%) Closing price 04:00 PM EasternExtended Trading$5.86 +0.01 (+0.09%) As of 06:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Oncology Institute Stock (NASDAQ:TOI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Oncology Institute alerts:Sign Up Key Stats Today's Range$5.59▼$6.1150-Day Range$3.44▼$5.8052-Week Range$2.32▼$6.11Volume1.99 million shsAverage Volume1.91 million shsMarket Capitalization$578.21 millionP/E RatioN/ADividend YieldN/APrice Target$8.40Consensus RatingModerate Buy Company Overview The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies. It serves adult and senior cancer patients. The company has a strategic collaboration with Healthly Forge to offer cancer care services to patients in Southern California. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California. Read More Oncology Institute Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks82nd Percentile Overall ScoreTOI MarketRank™: Oncology Institute scored higher than 82% of companies evaluated by MarketBeat, and ranked 89th out of 845 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingModerate Buy Consensus RatingOncology Institute has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 5 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialOncology Institute has a consensus price target of $8.40, representing about 43.6% upside from its current price of $5.85.Amount of Analyst CoverageOncology Institute has only been the subject of 4 research reports in the past 90 days.Read more about Oncology Institute's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Oncology Institute are expected to grow in the coming year, from ($0.17) to ($0.12) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Oncology Institute is -15.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oncology Institute is -15.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Oncology Institute's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.08% of the float of Oncology Institute has been sold short.Short Interest Ratio / Days to CoverOncology Institute has a short interest ratio ("days to cover") of 3.31, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Oncology Institute has recently increased by 4.14%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOncology Institute does not currently pay a dividend.Dividend GrowthOncology Institute does not have a long track record of dividend growth. News and Social Media4.3 / 5News Sentiment0.81 News SentimentOncology Institute has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Oncology Institute this week, compared to 3 articles on an average week.Search Interest9 people have searched for TOI on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows11 people have added Oncology Institute to their MarketBeat watchlist in the last 30 days. This is an increase of 450% compared to the previous 30 days. Company Ownership2.7 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $27,472.00 in company stock, which represents 0.0048% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Oncology Institute insiders have bought 5.96% more of their company's stock than they have sold. Specifically, they have bought $488,655.00 in company stock and sold $461,183.00 in company stock.Percentage Held by Insiders4.40% of the stock of Oncology Institute is held by insiders.Percentage Held by Institutions36.86% of the stock of Oncology Institute is held by institutions.Read more about Oncology Institute's insider trading history. Receive TOI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oncology Institute and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TOI Stock News HeadlinesThe Oncology Institute Completes Strategic Refinancing with OrbiMed, Repaying the Outstanding $86 Million Deerfield Convertible Note, Strengthening its Balance Sheet, and ...July 7 at 1:48 PM | markets.businessinsider.comWhy Oncology Institute’s (TOI) Analyst Upgrades Put Its Community Cancer Care Growth Story in FocusJuly 7 at 1:48 PM | finance.yahoo.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.July 9 at 1:00 AM | Porter & Company (Ad)The Oncology Institute Completes Strategic Refinancing with OrbiMed, Repaying the Outstanding $86 Million Deerfield Convertible Note, Strengthening its Balance Sheet, and Improving LiquidityJuly 7 at 9:00 AM | globenewswire.comOncology Institute (NASDAQ:TOI) Major Shareholder Acquires 18,000 Shares of StockJune 25, 2026 | insidertrades.comYale Podnos Sells 23,451 Shares of Oncology Institute (NASDAQ:TOI) StockJune 10, 2026 | insidertrades.comTopicus.com Inc. Announces a Revised Proposal to Acquire ReadyTechMay 31, 2026 | globenewswire.comThe Oncology Institute Chief Medical Officer to Speak on Value-Based Specialty Care at APG Spring ConferenceMay 26, 2026 | globenewswire.comSee More Headlines TOI Stock Analysis - Frequently Asked Questions How have TOI shares performed this year? Oncology Institute's stock was trading at $3.56 on January 1st, 2026. Since then, TOI shares have increased by 64.3% and is now trading at $5.85. How were Oncology Institute's earnings last quarter? The Oncology Institute, Inc. (NASDAQ:TOI) posted its quarterly earnings data on Thursday, May, 7th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.05. The business earned $147.44 million during the quarter, compared to analysts' expectations of $142.10 million. Read the conference call transcript. Who are Oncology Institute's major shareholders? Top institutional investors of Oncology Institute include Fermata Advisors LLC (0.01%). Insiders that own company stock include Jorey Chernett, Growth I LP M33, Daniel Virnich, Brad Hively, Yale Podnos, Robert Ross Carter, Mark L Pacala, Mohit Kaushal and Havencrest Healthcare Partners. View institutional ownership trends. How do I buy shares of Oncology Institute? Shares of TOI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Oncology Institute own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oncology Institute investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Arista Networks (ANET), Adobe (ADBE), AppLovin (APP) and CrowdStrike (CRWD). Company Calendar Last Earnings5/07/2026Today7/09/2026Next Earnings (Estimated)8/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (17m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 TOI's financial health is in the Green zone, according to TradeSmith. TOI has been in this zone for over 17 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical Services Sub-IndustryHealthcare Current SymbolNASDAQ:TOI CIK1799191 Webtheoncologyinstitute.com Phone562-735-3226FaxN/AEmployees660Year Founded2007Price Target and Rating Average Price Target for Oncology Institute$8.40 High Price Target$10.00 Low Price Target$7.00 Potential Upside/Downside+43.6%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($0.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$60.61 million Net Margins-7.42% Pretax Margin-8.00% Return on EquityN/A Return on Assets-24.68% Debt Debt-to-Equity RatioN/A Current Ratio1.47 Quick Ratio1.17 Sales & Book Value Annual Sales$502.73 million Price / Sales1.15 Cash FlowN/A Price / Cash FlowN/A Book Value($0.16) per share Price / Book-36.56Miscellaneous Outstanding Shares98,840,000Free Float94,490,000Market Cap$578.21 million OptionableNot Optionable Beta0.36 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:TOI) was last updated on 7/9/2026 by MarketBeat.com Staff. From Our PartnersDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding The Oncology Institute, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncology Institute With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
